[1] J. D. Hardy, W. R. Webb, M. L. Dalton, and G. R. Walker, “Lung Homotransplantation in Man,” JAMA, vol. 186, no. 12, pp. 1065–1074, Dec. 1963.
[2] J. D. Cooper, F. G. Pearson, G. A. Patterson, T. R. Todd, R. J. Ginsberg, M. Goldberg, and W. A. DeMajo, “Technique of successful lung transplantation in humans.,” J. Thorac. Cardiovasc. Surg., vol. 93, no. 2, pp. 173–81, Feb. 1987.
[3] 中島 淳, “肺移植の現状と展望,” 外科, vol. 80, no. 2, pp. 123–126, 2018.
[4] 日本移植学会, “Fact book 2016 of Organ Transplantation in Japan,” 2016. [Online]. Available: http://www.asas.or.jp/jst/pdf/factbook/factbook2017.pdf. [Accessed: 12- Nov-2018].
[5] D. C. Chambers, W. S. Cherikh, S. B. Goldfarb, D. Hayes, A. Y. Kucheryavaya, A. E. Toll, K. K. Khush, B. J. Levvey, B. Meiser, J. W. Rossano, and J. Stehlik, “The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report— 2018; Focus theme: Multiorgan Transplantation,” J. Hear. Lung Transplant., vol. 37, no. 10, pp. 1169–1183, 2018.
[6] R. D. Yusen, L. B. Edwards, A. Y. Kucheryavaya, C. Benden, A. I. Dipchand, S. B. Goldfarb, B. J. Levvey, L. H. Lund, B. Meiser, J. W. Rossano, and J. Stehlik, “The Registry of the International Society for Heart and Lung Transplantation: Thirty second Official Adult Lung and Heart-Lung Transplantation Report-2015; Focus Theme: Early Graft Failure,” J. Hear. Lung Transplant., vol. 34, pp. 1264–1277, 2015.
[7] 三好健太郎，大藤剛宏, “肺移植後遠隔期管理における課題,” 移植, vol. 51, no. 4･5, pp. 319–323, 2016.
[8] J. D. Christie, D. Van Raemdonck, M. De Perrot, M. Barr, S. Keshavjee, S. Arcasoy, and J. Orens, “Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part I: Introduction and Methods,” 2005.
[9] J. D. Christie, J. E. Bavaria, H. I. Palevsky, L. Litzky, N. P. Blumenthal, L. R. Kaiser, and R. M. Kotloff, “Primary graft failure following lung transplantation,” Chest, vol. 114, no. 1, pp. 51–60, 1998.
[10] J. D. Christie, R. M. Kotloff, A. Pochettino, S. M. Arcasoy, B. R. Rosengard, J. R. Landis, and S. E. Kimmel, “Clinical Risk Factors for Primary Graft Failure Following Lung Transplantation,” Chest, vol. 124, no. 4, pp. 1232–1241, 2003.
[11] R. C. King, O. A. . Binns, F. Rodriguez, R. C. Kanithanon, T. M. Daniel, W. D. Spotnitz, C. G. Tribble, and I. L. Kron, “Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation,” Ann. Thorac. Surg., vol. 69, no. 6, pp. 1681–1685, Jun. 2000.
[12] S. U. Khan, J. Salloum, P. B. O’Donovan, E. J. Mascha, A. C. Mehta, M. A. Matthay, and A. C. Arroliga, “Acute pulmonary edema after lung transplantation: The pulmonary reimplantation response,” Chest, vol. 116, no. 1, pp. 187–194, 1999.
[13] J. D. Christie, M. Carby, R. Bag, P. Corris, M. Hertz, and D. Weill, “Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation,” J. Hear. Lung Transplant., vol. 24, no. 10, pp. 1454–1459, 2005.
[14] M. L. Barr, S. M. Kawut, T. P. Whelan, R. Girgis, H. Böttcher, J. Sonett, W. Vigneswaran, D. M. Follette, P. A. Corris, M. De Perrot, R. S. Bonser, J. Dark, R. F. Kelly, D. McGiffin, R. Menza, O. Pajaro, S. Schueler, G. M. Verleden, M. L. Barr, S. M. Kawut, T. P. Whelan, R. Girgis, H. Böttcher, J. Sonett, W. Vigneswaran, D. M. Follette, and P. A. Corris, “Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: Recipient-related risk factors and markers,” J. Hear. Lung Transplant., vol. 24, no. 10, pp. 1468–1482, 2005.
[15] G. I. Snell, R. D. Yusen, D. Weill, M. Strueber, E. Garrity, A. Reed, A. Pelaez, T. P. Whelan, M. Perch, R. Bag, M. Budev, P. A. Corris, M. M. Crespo, C. Witt, E. Cantu, and J. D. Christie, “ISHLT CONSENSUS REPORTS PRIMARY LUNG GRAFT DYSFUNCTION Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation,” J. Hear. Lung Transplant., vol. 36, pp. 1097–1103, 2017.
[16] M. Anraku, M. J. Cameron, T. K. Waddell, M. Liu, T. Arenovich, M. Sato, M. Cypel, A. F. Pierre, M. De Perrot, D. J. Kelvin, and S. Keshavjee, “Impact of human donor lung gene expression profiles on survival after lung transplantation: A case-control study,” Am. J. Transplant., vol. 8, no. 10, pp. 2140–2148, 2008.
[17] T. N. Machuca, M. Cypel, J. C. Yeung, R. Bonato, R. Zamel, M. Chen, S. Azad, M. K. Hsin, T. Saito, Z. Guan, T. K. Waddell, M. Liu, and S. Keshavjee, “Protein expression profiling predicts graft performance in clinical ex vivo lung perfusion,” Ann. Surg., vol. 261, no. 3, pp. 591–597, 2015.
[18] M. De Perrot, R. S. Bonser, J. Dark, R. F. Kelly, D. McGiffin, R. Menza, O. Pajaro, S. Schueler, and G. M. Verleden, “Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: Donor-related risk factors and markers,” J. Hear. Lung Transplant., vol. 24, no. 10, pp. 1460–1467, 2005.
[19] M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee, “Ischemia-reperfusion-induced lung injury.,” Am. J. Respir. Crit. Care Med., vol. 167, no. 4, pp. 490–511, 2003.
[20] M. I. Morrison, T. L. Pither, and A. J. Fisher, “Pathophysiology and classification of primary graft dysfunction after lung transplantation,” J. Thorac. Dis., vol. 9, no. 10, pp. 4084–4097, 2017.
[21] B. A. Whitson, D. S. Nath, A. C. Johnson, A. R. Walker, M. E. Prekker, D. M. Radosevich, C. S. Herrington, and P. S. Dahlberg, “Risk factors for primary graft dysfunction after lung transplantation,” The Journal of Thoracic and Cardiovascular Surgery, vol. 131, no. 1. p. 73, 2006.
[22] A. E. Gelman, A. J. Fisher, H. J. Huang, M. A. Baz, C. M. Shaver, T. M. Egan, and M. S. Mulligan, “Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation,” Journal of Heart and Lung Transplantation, vol. 36, no. 10, Elsevier, pp. 1114–1120, 01-Oct-2017.
[23] C. L. Kuntz, D. Hadjiliadis, V. N. Ahya, R. M. Kotloff, A. Pochettino, J. Lewis, and J. D. Christie, “Risk factors for early primary graft dysfunction after lung transplantation: A registry study,” Clin. Transplant., vol. 23, no. 6, pp. 819–830, 2009.
[24] Y. Liu, Y. Liu, L. Su, and S. J. Jiang, “Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: A systematic review and metaanalysis,” PLoS One, vol. 9, no. 3, 2014.
[25] D. J. Lederer, J. S. Wilt, F. D’Ovidio, M. D. Bacchetta, L. Shah, S. Ravichandran, J. Lenoir, B. Klein, J. R. Sonett, and S. M. Arcasoy, “Obesity and underweight are associated with an increased risk of death after lung transplantation,” Am. J. Respir. Crit. Care Med., vol. 180, no. 9, pp. 887–895, 2009.
[26] D. J. Lederer, S. M. Kawut, N. Wickersham, C. Winterbottom, S. Bhorade, S. M. Palmer, J. Lee, J. M. Diamond, K. M. Wille, A. Weinacker, V. N. Lama, M. Crespo, J. B. Orens, J. R. Sonett, S. M. Arcasoy, L. B. Ware, and J. D. Christie, “Obesity and primary graft dysfunction after lung transplantation: The lung transplant outcomes group obesity study,” Am. J. Respir. Crit. Care Med., vol. 184, no. 9, pp. 1055–1061, 2011.
[27] A. Fang, S. Studer, S. M. Kawut, V. N. Ahya, J. Lee, K. Wille, V. Lama, L. Ware, J. Orens, A. Weinacker, S. M. Palmer, M. Crespo, D. J. Lederer, C. S. Deutschman, B. A. Kohl, S. Bellamy, E. Demissie, and J. D. Christie, “Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis,” Chest, vol. 139, no. 4, pp. 782–787, 2011.
[28] V. Transfer, “Silicone Rubber as a Selective Barrier,” vol. 49, no. 10, pp. 1685–1686, 1957.
[29] M. K. Porteous, J. C. Lee, D. J. Lederer, S. M. Palmer, E. Cantu, R. J. Shah, S. L. Bellamy, V. N. Lama, S. M. Bhorade, M. M. Crespo, J. F. McDyer, K. M. Wille, A. R. Localio, J. B. Orens, P. D. Shah, A. B. Weinacker, S. Arcasoy, D. S. Wilkes, L. B. Ware, J. D. Christie, S. M. Kawut, and J. M. Diamond, “Clinical risk factors and prognostic model for primary graft dysfunction after lung transplantation in patients with pulmonary hypertension,” Ann. Am. Thorac. Soc., vol. 14, no. 10, pp. 1514–1522, 2017.
[30] M. Nagendran, M. Maruthappu, and K. Sugand, “Should double lung transplant be performed with or without cardiopulmonary bypass?,” Interact. Cardiovasc. Thorac. Surg., vol. 12, no. 5, pp. 799–804, 2011.
[31] G. Thabut, I. Vinatier, J. B. Stern, G. Lesèche, P. Loirat, M. Fournier, and H. Mal, “Primary graft failure following lung transplantation: Predictive factors of mortality,” Chest, vol. 121, no. 6, pp. 1876–1882, 2002.
[32] M. W. Aaron and E. H. Grant, “Comparison between the dielectric properties of α- and β-alanine solutions,” Trans. Faraday Soc., vol. 63, pp. 2177–2180, 1967.
[33] D. Shah, F. Romero, W. Stafstrom, M. Duong, and R. Summer, “Extracellular ATP mediates the late phase of neutrophil recruitment to the lung in murine models of acute lung injury,” AJP Lung Cell. Mol. Physiol., vol. 306, no. 2, pp. L152–L161, 2014.
[34] G. Liu, A. T. Place, Z. Chen, V. M. Brovkovych, S. M. Vogel, W. A. Muller, R. A. Skidgel, A. B. Malik, and R. D. Minshall, “ICAM-1-activated Src and eNOS signaling increase endothelial cell surface PECAM-1 adhesivity and neutrophil transmigration,” Blood, vol. 120, no. 9, pp. 1942–1952, 2012.
[35] G. Liu, S. M. Vogel, X. Gao, K. Javaid, G. Hu, S. M. Danilov, A. B. Malik, and R. D. Minshall, “Src phosphorylation of endothelial cell surface intercellular adhesion molecule-1 mediates neutrophil adhesion and contributes to the mechanism of lung inflammation,” Arterioscler. Thromb. Vasc. Biol., vol. 31, no. 6, pp. 1342–1350, 2011.
[36] D. M. Sayah, B. Mallavia, F. Liu, G. Ortiz-Muñoz, A. Caudrillier, A. DerHovanessian, D. J. Ross, J. P. Lynch, R. Saggar, A. Ardehali, L. B. Ware, J. D. Christie, J. A. Belperio, M. R. Looney, S. M. Kawut, E. Cantu, J. Diamond, R. Shah, E. Demissie, R. M. Kotloff, V. N. Ayha, J. Lee, D. Hadjiliadis, M. Ruschefski, D. J. Lederer, S. M. Arcasoy, J. R. Sonett, J. Wilt, F. D’Ovidio, M. Bacchetta, H. Robbins, L. Shah, N. Ravichandran, N. Al-Naamani, N. Philip, D. Rybak, M. Lippell, S. Sanyal, M. Koeckert, A. Desai, M. Larkin, B. Lim, J. Shin, R. Sorabella, S. Logan, A. Weinacker, G. Dillon, S. S. Jacobs, V. Scott, K. Wille, D. McGiffin, N. Harris, J. Orens, A. Shah, P. Shah, J. McDyer, V. Lama, F. Martinez, E. Galopin, S. M. Palmer, J. Todd, L. Snyder, R. D. Davis, A. Finlen-Copeland, S. Bhorade, M. Crespo, C. Gries, J. P. Lynch Iii, R. Saggar, A. Ardehali, L. B. Ware, J. D. Christie, J. A. Belperio, and M. R. Looney, “Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation,” Am. J. Respir. Crit. Care Med., vol. 191, no. 4, pp. 455– 463, 2015.
[37] M. Cypel, J. C. Yeung, M. Liu, M. Anraku, F. Chen, W. Karolak, M. Sato, J. Laratta, S. Azad, M. Madonik, C.-W. Chow, C. Chaparro, M. Hutcheon, L. G. Singer, A. S. Slutsky, K. Yasufuku, M. de Perrot, A. F. Pierre, T. K. Waddell, and S. Keshavjee, “Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation,” N. Engl. J. Med., vol. 364, no. 15, pp. 1431–1440, 2011.
[38] A. Amital, D. Shitrit, Y. Raviv, M. Saute, B. Medalion, L. Bakal, and M. R. Kramer, “The use of surfactant in lung transplantation,” Transplantation, vol. 86, no. 11, pp. 1554–1559, 2008.
[39] A. K. Sharma, L. G. Fernandez, A. S. Awad, I. L. Kron, and V. E. Laubach, “Proinflammatory response of alveolar epithelial cells is enhanced by alveolar macrophage-produced TNF-α during pulmonary ischemia-reperfusion injury,” Am. J. Physiol. Cell. Mol. Physiol., vol. 293, no. 1, pp. L105–L113, Jul. 2007.
[40] M. L. Stone, A. K. Sharma, V. R. Mas, R. C. Gehrau, D. P. Mulloy, Y. Zhao, C. L. Lau, I. L. Kron, M. E. Huerter, and V. E. Laubach, “Ex vivo perfusion with adenosine A2A receptor agonist enhances rehabilitation of murine donor lungs after circulatory death,” Transplantation, vol. 99, no. 12, pp. 2494–2503, 2015.
[41] V. N. Lama, J. P. Eu, and M. R. Nicolls, “Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop,” J Clin Investig. Insight, vol. 2, no. 9, p. e93121, 2017.
[42] W. Jungraithmayr, I. De Meester, V. Matheeussen, I. Inci, K. Augustyns, S. Scharpé, W. Weder, and S. Korom, “Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide,” Peptides, vol. 31, no. 4, pp. 585–591, 2010.
[43] E. Silk, H. Zhao, H. Weng, and D. Ma, “The role of extracellular histone in organ injury,” Cell death & disease, vol. 8, no. 5. p. e2812, 2017.
[44] B. D. Strahl and C. David Allis, “The language of covalent histone modifications,” NATURE, vol. 403. pp. 41–45, 2000.
[45] M. L. Ekaney, G. P. Otto, M. Sossdorf, C. Sponholz, M. Boehringer, W. Loesche, D. Rittirsch, A. Wilharm, O. Kurzai, M. Bauer, and R. A. Claus, “Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation,” Crit. Care, vol. 18, no. 5, 2014.
[46] J. Xu, X. Zhang, R. Pelayo, M. Monestier, C. T. Ammollo, F. Semeraro, F. B. Taylor, N. L. Esmon, F. Lupu, and C. T. Esmon, “Extracellular histones are major mediators of death in sepsis,” Nat. Med., vol. 15, no. 11, pp. 1318–1321, 2009.
[47] S. T. Abrams, N. Zhang, J. Manson, T. Liu, C. Dart, F. Baluwa, S. S. Wang, K. Brohi, A. Kipar, W. Yu, G. Wang, and C.-H. H. Toh, “Circulating histones are mediators of trauma-associated lung injury,” Am. J. Respir. Crit. Care Med., vol. 187, no. 2, pp. 160–169, 2013.
[48] R. Allam, S. V. R. Kumar, M. N. Darisipudi, and H.-J. J. Anders, “Extracellular histones in tissue injury and inflammation,” J. Mol. Med., vol. 92, no. 5, pp. 465–472, 2014.
[49] S. F. De Meyer, G. L. Suidan, T. A. Fuchs, M. Monestier, and D. D. Wagner, “Extracellular chromatin is an important mediator of ischemic stroke in mice,” Arterioscler. Thromb. Vasc. Biol., vol. 32, no. 8, pp. 1884–1891, 2012.
[50] J. D. Gilthorpe, F. Oozeer, J. Nash, M. Calvo, D. L. Bennett, A. Lumsden, and A. Pini, “Extracellular histone H1 is neurotoxic and drives a pro-inflammatory response in microglia,” F1000Research, 2013.
[51] B. Vogel, H. Shinagawa, U. Hofmann, G. Ertl, and S. Frantz, “Acute DNase1 treatment improves left ventricular remodeling after myocardial infarction by disruption of free chromatin,” Basic Res. Cardiol., vol. 110, no. 2, p. 15, 2015.
[52] A. S. Savchenko, J. I. Borissoff, K. Martinod, S. F. De Meyer, M. Gallant, L. Erpenbeck, A. Brill, Y. Wang, and D. D. Wagner, “VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice,” Blood, vol. 123, no. 1, pp. 141–148, Jan. 2014.
[53] H. Huang, H.-W. Chen, J. Evankovich, W. Yan, B. R. Rosborough, G. W. Nace, Q. Ding, P. Loughran, D. Beer-Stolz, T. R. Billiar, C. T. Esmon, and A. Tsung, “Histones Activate the NLRP3 Inflammasome in Kupffer Cells during Sterile Inflammatory Liver Injury,” J. Immunol., vol. 191, no. 5, pp. 2665–2679, 2013.
[54] Z. Wen, Y. Liu, F. Li, F. Ren, D. Chen, X. Li, and T. Wen, “Circulating histones exacerbate inflammation in mice with acute liver failure,” J. Cell. Biochem., vol. 114, no. 10, pp. 2384–2391, 2013.
[55] H. Huang, J. Evankovich, W. Yan, G. Nace, L. Zhang, M. Ross, X. Liao, T. Billiar, J. Xu, C. T. Esmon, and A. Tsung, “Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice,” Hepatology, vol. 54, no. 3, pp. 999–1008, 2011.
[56] H. Huang, S. Tohme, A. B. Al-Khafaji, S. Tai, P. Loughran, L. Chen, S. Wang, J. Kim, T. Billiar, Y. Wang, and A. Tsung, “Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury.,” Hepatology, vol. 62, no. 2, pp. 600–14, Aug. 2015.
[57] X. Ou, Z. Cheng, T. Liu, Z. Tang, W. Huang, P. Szatmary, S. Zheng, R. Sutton, C. H. Toh, N. Zhang, and G. Wang, “Circulating Histone Levels Reflect Disease Severity in Animal Models of Acute Pancreatitis,” Pancreas, vol. 44, no. 7, pp. 1089–1095, Oct. 2015.
[58] R. Allam, C. R. Scherbaum, M. N. Darisipudi, S. R. Mulay, H. Hagele, J. Lichtnekert, J. H. Hagemann, K. V. Rupanagudi, M. Ryu, C. Schwarzenberger, B. Hohenstein, C. Hugo, B. Uhl, C. A. Reichel, F. Krombach, M. Monestier, H. Liapis, K. Moreth, L. Schaefer, and H.-J. Anders, “Histones from Dying Renal Cells Aggravate Kidney Injury via TLR2 and TLR4,” J. Am. Soc. Nephrol., vol. 23, no. 8, pp. 1375–1388, 2012.
[59] A. Caudrillier, K. Kessenbrock, B. M. Gilliss, J. X. Nguyen, M. B. Marques, M. Monestier, P. Toy, Z. Werb, and M. R. Looney, “Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury,” J. Clin. Invest., vol. 122, no. 7, pp. 2661–2671, 2012.
[60] M. Saffarzadeh, C. Juenemann, M. A. Queisser, G. Lochnit, G. Barreto, S. P. Galuska, J. Lohmeyer, and K. T. Preissner, “Neutrophil extracellular traps directly induce epithelial and endothelial cell death: A predominant role of histones,” PLoS One, vol. 7, no. 2, p. 32366, 2012.
[61] M. Bosmann, J. J. Grailer, R. Ruemmler, N. F. Russkamp, F. S. Zetoune, J. V. Sarma, T. J. Standiford, and P. A. Ward, “Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury,” FASEB J., vol. 27, no. 12, pp. 5010–5021, 2013.
[62] H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, R. Ohno, A. Hirayama, T. Matsuda, H. Asakura, M. Nakashima, and N. Aoki, “Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial,” J. Thromb. Haemost., vol. 5, no. 1, pp. 31–41, 2007.
[63] T. Ito, Y. Kakihana, and I. Maruyama, “Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases,” Expert Opin. Ther. Targets, vol. 20, no. 2, pp. 151–158, 2016.
[64] K. Osada, T. Minami, T. Arioka, T. Sakai, S. Tawara, K. Kawasaki, J. Fareed, and O. Matsuzaki, “Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation,” Thromb. Res., vol. 160, pp. 51–57, 2017.
[65] M. Nakahara, T. Ito, K. ichi Kawahara, M. Yamamoto, T. Nagasato, B. Shrestha, S. Yamada, T. Miyauchi, K. Higuchi, T. Takenaka, T. Yasuda, A. Matsunaga, Y. Kakihana, T. Hashiguchi, Y. Kanmura, and I. Maruyama, “Recombinant Thrombomodulin Protects Mice against Histone-Induced Lethal Thromboembolism,” PLoS One, vol. 8, no. 9, p. e75961, Sep. 2013.
[66] Y. Alhamdi, S. T. Abrams, Z. Cheng, S. Jing, D. Su, Z. Liu, S. Lane, I. Welters, G. Wang, and C.-H. H. Toh, “Circulating histones are major mediators of cardiac injury in patients with sepsis,” Crit. Care Med., vol. 43, no. 10, pp. 2094–2103, 2015.
[67] T. Iba, T. Hirota, K. Sato, I. Nagaoka, · Koichi Sato, and I. Nagaoka, “Protective effect of a newly developed fucose-deficient recombinant antithrombin against histoneinduced endothelial damage,” Int. J. Hematol., vol. 107, no. 5, pp. 528–534, May 2018.
[68] “旭化成ファーマ株式会社.” [Online]. Available: http://www.ak-hcc.com/. [Accessed: 14-Dec-2018].
[69] M. Mohri, Y. Gonda, M. Oka, Y. Aoki, K. Gomi, T. Kiyota, T. Sugihara, S. Yamamoto, T. Ishida, and I. Maruyama, “The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis).,” Blood Coagul. Fibrinolysis, vol. 8, no. 5, pp. 274–83, Jul. 1997.
[70] T. Goto, M. Kohno, M. Anraku, T. Ohtsuka, Y. Izumi, and H. Nomori, “Simplified rat lung transplantation using a new cuff technique,” Ann. Thorac. Surg., vol. 93, no. 6, pp. 2078–2080, 2012.
[71] R. Lucas, S. A. Langhans, C. Peteranderl, J. I. Sznajder, S. Herold, and E. Lecuona, “inflammatory Responses Regulating Alveolar ion Transport during Pulmonary infections,” vol. 8, p. 446, 2017.
[72] D. L. Laskin, R. Malaviya, and J. D. Laskin, “Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants,” Toxicol. Sci., Dec. 2018.
[73] A. Ushiyama, H. Kataoka, and T. Iijima, “Glycocalyx and its involvement in clinical pathophysiologies,” J. Intensive Care, vol. 4, no. 1, p. 59, 2016.
[74] M. Stegnar, N. Vene, and M. Bozic, “Do haemostasis activation markers that predict cardiovascular disease exist?,” in Pathophysiology of Haemostasis and Thrombosis, 2003, vol. 33, no. 5–6, pp. 302–308.
[75] H. Feng, W. Guo, J. Han, and X.-A. Li, “Role of caveolin-1 and caveolae signaling in endotoxemia and sepsis,” 2013.
[76] H. Gao, Y. Tian, W. Wang, D. Yao, T. Zheng, and Q. Meng, “Levels of interleukin-6, superoxide dismutase and malondialdehyde in the lung tissue of a rat model of hypoxia-induced acute pulmonary edema.,” Exp. Ther. Med., vol. 11, no. 3, pp. 993–997, Mar. 2016.
[77] C. E. Rose, S. S. J. Sung, and S. M. Fu, “Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung,” Microcirculation, vol. 10, no. 3–4, pp. 273–288, 2003.
[78] M. Schuliga, G. Westall, Y. Xia, and A. G. Stewart, “The plasminogen activation system: New targets in lung inflammation and remodeling,” Current Opinion in Pharmacology, vol. 13, no. 3. pp. 386–393, 2013.
[79] B. Grünwald, B. Schoeps, and A. Krüger, “Recognizing the Molecular Multifunctionality and Interactome of TIMP-1,” Trends in Cell Biology, 2018.
[80] Z. Zhang, Z. Wu, Y. Xu, D. Lu, and S. Zhang, “Vascular endothelial growth factor increased the permeability of respiratory barrier in acute respiratory distress syndrome model in mice,” Biomed. Pharmacother., vol. 109, pp. 2434–2440, 2019.
[81] N. T. Gatto, A. W. Confer, D. M. Estes, L. C. Whitworth, and G. L. Murphy, “Lung Lesions in SCID-bo and SCID-bg Mice after Intratracheal Inoculation with Wild-type or Leucotoxin-deficient Mutant Strains of Mannheimia haemolytica Serotype 1,” J. Comp. Pathol., vol. 134, no. 4, pp. 355–365, 2006.
[82] Y. Toyoda, J. K. Bhama, N. Shigemura, D. Zaldonis, J. Pilewski, M. Crespo, and C. Bermudez, “Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation,” J. Thorac. Cardiovasc. Surg., vol. 145, no. 4, pp. 1065–1071, 2013.
[83] D. Van Raemdonck, A. Neyrinck, M. Cypel, and S. Keshavjee, “Ex-vivo lung perfusion,” Transpl. Int., vol. 28, no. 6, pp. 643–656, Jun. 2015.
[84] Y. Alhamdi, M. Zi, S. T. Abrams, T. Liu, D. Su, I. Welters, T. Dutt, E. J. Cartwright, G. Wang, and C.-H. H. Toh, “Circulating histone concentrations differentially affect the predominance of left or right ventricular dysfunction in critical illness,” Crit. Care Med., vol. 44, no. 5, pp. e278–e288, May 2016.
[85] T. Kusano, K. C. Chiang, M. Inomata, Y. Shimada, N. Ohmori, T. Goto, S. Sato, S. Goto, T. Nakano, S. Kawamoto, Y. Takaoka, N. Shiraishi, T. Noguchi, and S. Kitano, “A novel anti-histone H1 monoclonal antibody, SSV monoclonal antibody, improves lung injury and survival in a mouse model of lipopolysaccharide-induced sepsis-like syndrome,” Biomed Res. Int., vol. 2015, 2015.
[86] S. Barranco-Medina, N. Pozzi, A. D. Vogt, and E. Di Cera, “Histone H4 Promotes Prothrombin Autoactivation *,” 2013.
[87] C. T. AMMOLLO, F. SEMERARO, J. XU, N. L. ESMON, and C. T. ESMON, “Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation,” J. Thromb. Haemost., vol. 9, no. 9, pp. 1795–1803, Sep. 2011.
[88] S. Geiger, S. Holdenrieder, P. Stieber, G. F. Hamann, R. Bruening, J. Ma, D. Nagel, and D. Seidel, “Nucleosomes in Serum of Patients with Early Cerebral Stroke,” Cerebrovasc Dis, vol. 21, pp. 32–37, 2006.
論文の公開元へ
